Mouse anti Bromodeoxyuridine / BrdU
| Code | Size | Price |
|---|
| MUB0200P | 0.1 mg | £326.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: IIB5
Regulatory Status: RUO
Applications:
- Flow Cytometry
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
Storage:
Store at 4°C or in small aliquots at -20°C.
Documents
Further Information
Applications Description:
IIB5 is suitable for flow cytometry and immunohistochemistry on frozen and paraffin-embedded tissues. Optimal antibody dilution should be determined by titration; recommended range is 1:100 ? 1:200 for flow cytometry, and for immunohistochemistry with avidin-biotinylated Horseradish peroxidase complex (ABC) as detection reagent.
Background:
The immunocytochemical detection of bromodeoxyuridine (BrdU) incorpoRated into DNA is a powerful tool to study the cytokinetics of normal and neoplastic cells. In vitro or in vivo labeling of tumor cells with the thymidine analogue BrdU and the subsequent detection of incorpoRated BrdU with specific anti-BrdU monoclonal antibodies is an accuRate and comprehensive method to quantitate the degree of DNA-synthesis. BrdU is incorpoRated into the newly synthezised DNA of the S-phase cells and can thus provide an estimate for the fraction of cells in S-phase. Also dynamic prolifeRative information (such as the S-phase transit Rate and the potential doubling time) can be obtained, by means of bivariate BrdU/DNA flow cytometric analysis.
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
This product contains sodium azide. To prevent formation of toxic vapors, do not mix with strong acidic solutions. To prevent formation of potentially explosive metallic azides in metal plumbing, always wash into drain with copious quantities of water.
This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
This product contains sodium azide. To prevent formation of toxic vapors, do not mix with strong acidic solutions. To prevent formation of potentially explosive metallic azides in metal plumbing, always wash into drain with copious quantities of water.
This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
Field of Interest:
Cancer|Cell cycle|Immunology|Neurobiology|Stem cell research
Formulation:
Each vial contains 100 ul 1 mg/ml purified monoclonal antibody in PBS containing 0.09% sodium azide.
Product:
Each vial contains 100 ul 1 mg/ml purified monoclonal antibody in PBS containing 0.09% sodium azide.
Source:
IIB5 is a Mouse monoclonal IgG1 antibody derived by fusion of SP2/0-Ag14 Mouse myeloma cells with spleen cells from a BALB/c Mouse intraperitoneally immunized with BrdU conjugated to Bovine Serum albumin.
Specificity:
IIB5 reacts with bromodeoxyuridine (BrdU) also when incorporated into nuclear DNA.The antibody is known to cross-react with Iododeoxyuridine (IdU). Although we have no specific information concerning chlorodeoxyuridine (CldU), it is to be expected that also this antigen is recognized by IIB5.
References
1. Schutte, B., Reynders, M. M., van Assche, C. L., Hupperets, P. S., Bosman, F. T., and Blijham, G. H. (1987). An improved method for the immunocytochemical detection of bromodeoxyuridine labeled nuclei using flow cytometry, Cytometry 8, 372-6.
2.
2. Tinnemans, M. M., Schutte, B., Lenders, M. H., Ten Velde, G. P., Ramaekers, F. C., and Blijham, G. H. (1993). Cytokinetic analysis of lung cancer by in vivo bromodeoxyuridine labelling, Br J Cancer 67, 1217-22.
3.
3. Schutte, B., Tinnemans M.M.F.J., Pijpers, G.F.P., Lenders, M.J.H. and Ramaekers, F. (1995). Three parameter flow cytometric analysis for simultaneous detection of cytokeratin, proliferation associated antigens and DNA content. Cytometry 21, 177-86.
4.
4. van Engeland, M., Kuijpers, H. J., Ramaekers, F. C., Reutelingsperger, C. P., and Schutte, B. (1997). Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res 235, 421-430.
5.
5. Schutte, B., Nieland, L., van Engeland, M., Henfling, M. E., Meijer, L., and Ramaekers, F. C. (1997). The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res 236, 4-15.
2.
2. Tinnemans, M. M., Schutte, B., Lenders, M. H., Ten Velde, G. P., Ramaekers, F. C., and Blijham, G. H. (1993). Cytokinetic analysis of lung cancer by in vivo bromodeoxyuridine labelling, Br J Cancer 67, 1217-22.
3.
3. Schutte, B., Tinnemans M.M.F.J., Pijpers, G.F.P., Lenders, M.J.H. and Ramaekers, F. (1995). Three parameter flow cytometric analysis for simultaneous detection of cytokeratin, proliferation associated antigens and DNA content. Cytometry 21, 177-86.
4.
4. van Engeland, M., Kuijpers, H. J., Ramaekers, F. C., Reutelingsperger, C. P., and Schutte, B. (1997). Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res 235, 421-430.
5.
5. Schutte, B., Nieland, L., van Engeland, M., Henfling, M. E., Meijer, L., and Ramaekers, F. C. (1997). The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res 236, 4-15.